Target intelligence / Profile preview

Cullin-3 (CUL3)

Target
CUL3
Molecular classification
E3 ubiquitin ligase scaffold protein, Ubiquitin–proteasome system component, Cullin protein family
01

Overview

Cullin-3 is a core scaffold protein of Cullin-RING E3 ubiquitin ligase complexes, fundamental to the ubiquitin–proteasome system that mediates the selective ubiquitination and proteasomal degradation of many proteins within the cell. CUL3 regulates a wide array of essential cellular processes—cell cycle progression, stress responses, protein trafficking, transcription, blood pressure regulation, and development—by recruiting various substrate-recognition proteins and linking them to the E2 ubiquitin-conjugating enzyme via the RING protein RBX1. Dynamic activation via neddylation (covalent attachment of the ubiquitin-like modifier NEDD8) is required for its ligase function. Genetic disruption of CUL3 leads to broad pathological effects, including neurodevelopmental disorders, hypertension, and cancer. CUL3 is studied as a potential therapeutic target and a biomarker, though direct pharmacologic inhibitors remain mostly investigational.

Other names
Cullin-3CUL3KIAA0617NEDAUSPHA2Ecullin-3
02

Mechanism of action

Inhibition of CUL3 neddylation → inhibition of E3 ubiquitin ligase activity (e.g., by NEDD8 pathway inhibitors). Modulation of protein homeostasis via altered substrate ubiquitination and degradation.

03

Biological functions

Protein ubiquitination and proteasomal degradationCell cycle regulationStress responseProtein traffickingSignal transductionDNA replicationTranscription modulationProtein quality controlCircadian rhythm regulationCellular developmentRegulation of blood pressure (via WNK1, WNK4 ubiquitination)Endosomal/lysosomal trafficking
04

Disease associations

CancerNeurodevelopmental disorders (e.g., CUL3-related neurodevelopmental disorder)Hypertension (pseudohypoaldosteronism type II/E)Cardiovascular diseaseOther disorders involving protein homeostasis
05

Safety considerations

Broad modulation of ubiquitination may lead to impairment of essential cellular processesPotential for adverse effects on neurodevelopment, cardiovascular function, cell cycle, and tissue homeostasisDeletion or severe dysfunction of CUL3 is embryonically lethal in mice
06

Interacting drugs

There are currently no widely approved, specific drugs targeting Cullin-3 directly in clinical use. However, modulators of the neddylation pathway (e.g., MLN4924/pevonedistat, a general NEDD8-activating enzyme inhibitor) affect CUL3 function indirectly.
07

Biomarkers

Cullin-3 expression level (potential cancer and neurodevelopmental disorder biomarker)Neddylation status of CUL3Mutation analysis for CUL3-related disorders

Beyond the preview

Go deeper on Cullin-3 (CUL3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cullin-3 (CUL3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call